Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding lab results in another language, especially when Sera Prognostics鈥� disclosures span clinical-trial endpoints, cash-burn tables and biomarker patents. If you have ever wondered how to track Sera Prognostics insider trading Form 4 transactions before pivotal data releases or needed to locate R&D spend buried deep in the notes, you know the challenge.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn a 300-page 10-K into a two-minute brief, flagging exactly where the company discusses pre-term birth biomarkers, partnership milestones and patent litigation risks. AG真人官方-time alerts surface every filing type the moment it hits EDGAR, including:
- Sera Prognostics quarterly earnings report 10-Q filing with segment growth and burn-rate trends
- Sera Prognostics annual report 10-K simplified for long-term obligations and IP strategy
- Sera Prognostics proxy statement executive compensation to benchmark leadership incentives
- Sera Prognostics 8-K material events explained for clinical-trial results or financing updates
- Sera Prognostics Form 4 insider transactions real-time so you never miss an executive stock move
Whether you鈥檙e analysing cash runway, comparing quarter-over-quarter biomarker adoption, or simply understanding Sera Prognostics SEC documents with AI, Stock Titan streamlines your workflow. Use the Sera Prognostics earnings report filing analysis to assess revenue from diagnostic sales, or dive into Sera Prognostics executive stock transactions Form 4 for sentiment signals. Complex biotech disclosures are now clear, timely and actionable鈥攏o scientific background required.
Sera Prognostics, Inc. (SERA) 鈥� Form 4 insider filing
On 7 July 2025, director Mansoor Raza Mirza reported the sale of 234 Class A common shares at $2.36 per share. The shares were automatically sold to cover federal and state tax-withholding obligations triggered by the vesting of previously granted restricted stock units ("RSUs"). The company鈥檚 tax-settlement policy requires a mandatory "sell-to-cover" transaction; therefore, the sale was not a discretionary disposition.
Following the transaction, Mirza鈥檚 direct beneficial ownership stands at 58,927 shares. No derivative securities transactions were reported, and there is no indication of additional open-market sales or purchases.
The size of the sale is immaterial relative to the insider鈥檚 remaining holdings, and because it was executed solely for tax purposes, the filing is neutral from a valuation or sentiment perspective.
Iron Mountain Incorporated (NYSE: IRM) filed a Form 4 on 8 July 2025 reporting insider activity by director Doyle R. Simons.
- Two acquisitions of derivative securities: 340.987 phantom shares on 3 July 2025 and 347.908 phantom shares on 7 July 2025, both coded 鈥淎鈥�.
- Plan-based transactions: The units were credited under the company鈥檚 Directors Deferred Compensation Plan; each phantom share mirrors one IRM common share and will be delivered after the director鈥檚 board service ends or upon disability.
- Post-transaction balance: Simons now holds 44,369.762 phantom shares, up by 688.895 units from the prior balance.
- Reference pricing: Column 8 lists weighted-average prices of $100.56 and $100.601, representing multiple trades executed between $100.419 and $100.624.
- Signal strength: Because the activity is compensation-related rather than open-market buying, the transactions are generally considered routine and carry limited market-moving impact.
Sera Prognostics Chief Commercial Officer Dyaarl Lee Anderson Jr. received significant equity compensation on June 23, 2025, consisting of two components:
- 67,114 Restricted Stock Units (RSUs) with a four-year vesting schedule: - 25% vests on June 10, 2026 - Remaining 75% vests quarterly over three years
- 102,534 Stock Options with strike price of $1.87: - 25% vests on June 10, 2026 - Remaining 75% vests monthly over three years
Both grants require continued service with the company. The equity awards suggest a long-term retention strategy for the Chief Commercial Officer position, with zero-cost RSUs balanced against performance-based stock options. The relatively low strike price of $1.87 indicates potential upside opportunity in the company's growth prospects.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
What is the primary focus of Sera Prognostics, Inc.?
How do Sera Prognostics' tests benefit healthcare providers?
What technology underpins Sera Prognostics' diagnostic tests?
How does Sera Prognostics differentiate itself in the diagnostic testing market?
Can you explain the significance of biomarker testing in maternal care?
What role do partnerships play in the company鈥檚 strategy?
What is the importance of clinical evidence for Sera Prognostics?
How is Sera Prognostics positioned within the broader maternal health diagnostic landscape?
